This week, seven biotechnology stocks are improving their overall rating on Portfolio Grader. Each of these rates an “A” (“strong buy”) or “B” overall (“buy”).
Stemline Therapeutics, Inc. (STML) is making headway this week, with the company’s rating improving to an A (“strong buy”) from a B (“buy”) last week. For more information, get Portfolio Grader’s complete analysis of STML stock.
This week, Pharmacyclics, Inc. (PCYC) is showing significant improvement as the company’s rating hops from a C (“hold”) to a B (“buy”). Pharmacyclics is a pharmaceutical company developing products to improve upon current therapeutic approaches to cancer, atherosclerosis, and retinal disease. For more information, get Portfolio Grader’s complete analysis of PCYC stock.
This week, Acorda Therapeutics, Inc.’s (ACOR) ratings are up from a C last week to a B. Acorda Therapeutics is a commercial stage biopharmaceutical company dedicated to the identification, development and commercialization of novel therapies that improve neurological function in people with multiple sclerosis (MS), spinal cord injury and other disorders of the central nervous system. Shares of the stock have been changing hands at an unusually rapid pace, twice the rate of the week prior. For more information, get Portfolio Grader’s complete analysis of ACOR stock.
Northwest Biotherapeutics, Inc. (NWBO) gets a higher grade this week, advancing from a C last week to a B. Northwest Biotherapeutics engages in discovering, developing, and commercializing immunotherapy products to treat cancers in the United States. For more information, get Portfolio Grader’s complete analysis of NWBO stock.
The rating of Amgen (AMGN) moves up this week, rising from a B to an A. Amgen discovers, develops, manufactures, and markets medicines for serious illnesses. The stock’s dividend yield is 2.4%. For more information, get Portfolio Grader’s complete analysis of AMGN stock.
BioMarin Pharmaceutical (BMRN) is seeing ratings go up from a C last week to a B this week. BioMarin Pharmaceutical develops and commercializes innovative pharmaceuticals for serious diseases and medical conditions. For more information, get Portfolio Grader’s complete analysis of BMRN stock.
Seattle Genetics, Inc. (SGEN) boosts its rating from a C to a B this week. Seattle Genetics is a clinical-stage biotechnology company that is focused on the development and commercialization of monoclonal antibody-based therapies for the treatment of cancer and autoimmune disease. For more information, get Portfolio Grader’s complete analysis of SGEN stock.
Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.